Navigation Links
Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Date:9/2/2008

this was reported 35 times by 19 women (23%) randomized to elagolix 150 mg once daily, 52 times by 22 women (26%) randomized to elagolix 75 mg twice daily, and 43 times by 12 (14%) women randomized to DMPA. There were two serious AEs that led to discontinuation from the trial, both in the DMPA group. The mean frequency of hot flashes was comparable in both the screening period and the treatment period, approximately 0.5 per day across all treatment groups, consistent with our prior Phase II studies.

"We couldn't be more pleased with the results of this study," said Kevin C. Gorman, President and Chief Executive Officer, Neurocrine Biosciences. "We began this program nine years ago with the hope of selectively modulating the GnRH system with an oral antagonist. This trial and our previous Phase II studies have now shown that this is possible. Elagolix is a first in class drug for endometriosis sufferers who desperately need a safe and effective therapy. This is apparent from the 8,000 inquiries to the call center for just this one study. Additionally, to date we had more than 6,000 inquiries regarding the ongoing Lilac PETAL study which is now fully enrolled and on track to report results in 2009."

"These study results are very encouraging," said Shayne M. Plosker, MD, Associate Professor and Division Director, of USF IVF and Reproductive Endocrinology at the University of South Florida College of Medicine in Tampa. "Elagolix has the potential to be an ideal advanced medical therapy for endometriosis-associated pelvic pain and dysmenorrhea. Intermediate suppression of estradiol by a well-tolerated drug appears attainable affording endometriosis symptom reduction without bone loss."

Neurocrine Biosciences would like to thank the patients and the investigators for participating in this important clinical trial.

Conference Call and Webcast Information

The Company will host a live conference call and webcast to provide additional detai
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
10. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
11. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013 Ambit Biosciences Corporation (Nasdaq: ... clinical investigations of quizartinib (AC220), a potent and selective ... of the American Society of Clinical Oncology, held May ... Chicago . Information ... listed below. Abstracts can be viewed online at ...
(Date:5/22/2013)... 22, 2013 /PRNewswire-iReach/ -- MarketReportsOnline.com announces addition of ... Series (4) 2013 Edition Material and Clinical Trial ... Registration: A Guidebook of Registration Application for Imported ... its online database. The traditional medicines ... always regarded by occidental as mysterious medicines. Until ...
(Date:5/22/2013)... May 22, 2013 Assured Pharmacy, Inc. (APHY), ... medications to sufferers of chronic pain, announced it has ... investor relations firm, to raise its visibility and strengthen ... the past year, we have proven our business model ... plans to open two additional new pharmacies in ...
Breaking Medicine Technology:Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology 2Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology 3China Pharmaceutical Market Guidebook Series (4) 2013 Report 2China Pharmaceutical Market Guidebook Series (4) 2013 Report 3China Pharmaceutical Market Guidebook Series (4) 2013 Report 4China Pharmaceutical Market Guidebook Series (4) 2013 Report 5Assured Pharmacy Hires Hayden IR 2Assured Pharmacy Hires Hayden IR 3
... Dec. 13, 2010 Out of hundreds ... Medicare DualChoice (HMO SNP) is one of only five plans across ... quality and performance from the Centers for Medicare and Medicaid Services ... how well health and drug plans perform on a scale of ...
... 13, 2010 Montefiore Medical Center has introduced a ... reflux disease (GERD), most commonly known as acid reflux. ... not require any incisions, recovery is faster and it ... next step in the evolution of surgery, which can ...
Cached Medicine Technology:IEHP Earns Highest Rating for Medicare Part D Quality and Performance 2Natural Orifice Surgery Introduced to Relieve Acid Reflux 2Natural Orifice Surgery Introduced to Relieve Acid Reflux 3
(Date:5/22/2013)... Garcinia cambogia select is a dual action fat burner ... fat being stored in the body. For a rapid weight ... burner helps people in this regard by making the consumer ... does this by secreting a hormone serotonin which makes people ... emotional overeating. In this way, it keeps a control on ...
(Date:5/22/2013)... Los Angeles, CA (PRWEB) May 22, 2013 ... board, The J. M. Smucker Company, and Danny ... Awards yesterday at the GS1 General Assembly and Global ... Mr. Smucker and Mr. Wegman were recognized for their ... Standards - the most broadly used supply chain standards ...
(Date:5/22/2013)... and teens exposed to radiation during CT scans are ... a large, long-term study. The risks, however, are ... who each had one CT scan, only about six ... years, according to researchers from Australia and Europe. ... to patients when making decisions about CT (computed tomography) ...
(Date:5/22/2013)... German . ... establishing 11 new Research Training Groups to further support ... by the relevant Grants Committee in Bonn. Funding of ... new programmes for an initial period of four and ... Research Training Groups, the Grants Committee approved the extension ...
(Date:5/22/2013)... encouraging a baby to finish the last ounce in their ... the calories soon burn off, a bad habit remains. , ... found that clinical obesity at 24 months of age strongly ... at age two, it puts you on a trajectory where ... adolescence and as an adult," said Forste. "That,s a big ...
Breaking Medicine News(10 mins):Health News:Garcinia Cambogia Reviews Released Online for Fast Weight Loss Solution with Offer of Extra 3 Month Supply 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 3Health News:Children Who Have CT Scans May Face Higher Cancer Risk 2Health News:DFG establishes 11 new research training groups 2Health News:DFG establishes 11 new research training groups 3Health News:DFG establishes 11 new research training groups 4Health News:DFG establishes 11 new research training groups 5Health News:Overeating learned in infancy, study suggests 2
... difference in effectiveness of 5 drugs currently available , , ... that any one of the five drugs available in ... the others, says an American College of Physicians (ACP) ... just issued a new guideline on drug treatment of ...
... Publishing, an award-winning interactive, visual content developer, today ... the first free, Web-based 3-D interactive model of ... educators, and health and medical professionals, The Visible ... how the human body works. It will also ...
... ANNAPOLIS, Md., March 4 Dozens of ... gathered in Annapolis today as,the General Assembly ... regulations, protections against identity theft, and the ... visited legislators,offices and attended committee hearings on ...
... Market Segments, CHICAGO, March 4 Throw ... Financial services firms, insurers, and,healthcare payors admit they ... to serve baby boomers, who will control some ... who make up the wealthiest generation in history, ...
... CA A nuclear receptor protein, known for controlling ... powerful anti-inflammatory effects in arteries, suppressing atherosclerosis in mice ... research by scientists at the Salk Institute for Biological ... , Their findings, reported in this weeks online edition ...
... swayed by adolescent drug use trends , , TUESDAY, March 4 ... boys are more likely to give up the habit if ... no matter what, new research shows. , The findings ... to the wider world,s embrace of illegal drugs, said study ...
Cached Medicine News:Health News:Groups Issue New Dementia Drug Guidelines 2Health News:Argosy publishing launches The Visible Body 2Health News:Argosy publishing launches The Visible Body 3Health News:Utilities, Long Term Care Bills at Center of 'AARP Day In Annapolis' 2Health News:Diamond's Retirement Study Finds Companies Ill-Prepared to Meet Baby Boomers' Health and Wealth Needs 2Health News:Diamond's Retirement Study Finds Companies Ill-Prepared to Meet Baby Boomers' Health and Wealth Needs 3Health News:Diamond's Retirement Study Finds Companies Ill-Prepared to Meet Baby Boomers' Health and Wealth Needs 4Health News:Diamond's Retirement Study Finds Companies Ill-Prepared to Meet Baby Boomers' Health and Wealth Needs 5Health News:New potential drug target for the treatment of atherosclerosis 2Health News:New potential drug target for the treatment of atherosclerosis 3Health News:Troubled Boys Will Abandon Pot When It's Deemed Uncool 2
... care management tools that support the nursing ... vital signs and I&O information at the ... on-line flow sheets. This design supports compliance ... the hall, or at the nursing station, ...
For superior bar code scanning performance with maximum user comfort at a highly attractive price, the LS 4000i Scanner Series from Symbol Technologies establishes an award-winning standard of excell...
... thermal transfer wristband for printing quality ... that resist smears and abrasion as ... and blood. A time-tested and proven ... management applications. A tamper-evident VOID version ...
... The DataMate Laser Sheeted ... consists of laser-printable sheets ... wristband and laser labels ... The wristbands clear, fold-over ...
Medicine Products: